logo
CyberArk Announces Strong First Quarter 2025 Results

CyberArk Announces Strong First Quarter 2025 Results

Business Wire13-05-2025

NEWTON, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)-- CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced strong financial results for the first quarter ended March 31, 2025.
'CyberArk delivered a strong start to 2025, highlighting the power of our unified platform and the durability of our business model,' said Matt Cohen, Chief Executive Officer of CyberArk. 'In Q1, total ARR reached $1.215 billion, driven by robust net new ARR of $46 million. Our consistent execution and ongoing innovation fueled strong top-line growth, while we continue to scale profitably — achieving an 18% non-GAAP operating margin and generating $96 million in free cash flow.'
'Our first quarter performance shows we continue to operate in a resilient demand environment. Identity security is a top priority for organizations, and customers are accelerating their roadmaps while consolidating spend on CyberArk's platform to drive security outcomes and operational efficiency. We are particularly pleased with the success of our machine identity business, with strong contributions from both Venafi and our Secrets Management solutions, showing we are delivering transformational value across all types of identities.'
'We're living in an exponential era: threats are accelerating, and the number of identities and privileges is multiplying across every enterprise. Human privileges have proliferated beyond traditional roles, machine identities now outnumber humans by more than 80-to-1, and AI agents are emerging as a new, rapidly growing identity group. These realities underscore why identity security is not optional — it's foundational. With the acquisition of Zilla Security and continued product innovation, CyberArk remains uniquely positioned as the only platform designed to discover, govern, provision, and enforce security controls across every identity — human, machine, and AI. With our first quarter performance, we are set up to deliver against our growth, profitability and free cash flow targets in 2025.'
Financial Summary for the First Quarter Ended March 31, 2025
The financial results for the first quarter of 2025 include the financial contributions from the acquisition of Venafi, which closed on October 1, 2024, and the financial contributions from the acquisition of Zilla Security, which closed on February 12, 2025. The financial results in the comparable period in 2024 did not include any financial contribution from these acquisitions.
Total revenue was $317.6 million in the first quarter of 2025, up 43 percent from $221.6 million in the first quarter of 2024.
Subscription revenue was $250.6 million in the first quarter of 2025, an increase of 60 percent from $156.2 million in the first quarter of 2024.
Maintenance, professional services and other revenue was $67.0 million in the first quarter of 2025, compared to $65.3 million in the first quarter of 2024.
GAAP operating loss was $(20.7) million compared to GAAP operating loss of $(6.4) million in the same period last year. Non-GAAP operating income was $57.5 million, or 18 percent margin, compared to non-GAAP operating income of $33.0 million, or 15 percent margin, in the same period last year.
GAAP net income was $11.5 million, or $0.22 per diluted share, compared to GAAP net income of $5.5 million, or $0.13 per diluted share, in the same period last year. Non-GAAP net income was $50.3 million, or $0.98 per diluted share, compared to non-GAAP net income of $35.9 million, or $0.75 per diluted share, in the same period last year.
Balance Sheet and Net Cash Provided by Operating Activities
As of March 31, 2025, cash, cash equivalents, short-term deposits, and marketable securities were $776.1 million. The changes in CyberArk's cash balance reflect approximately $165 million in cash paid for the acquisition of Zilla Security.
During the three months ended March 31, 2025, the Company's net cash provided by operating activities was $98.5 million, compared to $68.6 million in the three months ended March 31, 2024.
Key Business Highlights
Annual Recurring Revenue (ARR) was $1.215 billion, an increase of 50 percent from $811 million at March 31, 2024.
The Subscription portion of ARR was $1.028 billion, or 85 percent of total ARR at March 31, 2025. This represents an increase of 65 percent from $621 million, or 77 percent of total ARR, at March 31, 2024.
The Maintenance portion of ARR was $188 million at March 31, 2025, compared to $190 million at March 31, 2024.
Recurring revenue in the first quarter of 2025 was $298.2 million, an increase of 45 percent from $205.8 million for the first quarter of 2024.
Recent Developments
CyberArk Announced the Acquisition of Zilla Security, a Leader in modern Identity Governance and Administration (IGA) Solutions.
CyberArk Announces Identity Security Solution to Secure AI Agents At Scale.
CyberArk Unveils First-Of-Its-Kind Machine Identity Security Solution To Secure Workloads Across Every Environment.
CyberArk Bolsters Identity Security Platform with New Capabilities for Human, AI and Machine Identities.
CyberArk Strengthens Identity Security for AI Agents with Accenture's AI Refinery.
CyberArk Released its 2025 Identity Security Landscape Report, showing the Exponential Threats of Fragmented Identity Security.
CyberArk Released its 2025 State of Machine Identity Security Report, showing Rapid Growth of Machine Identities, AI Adoption and Cloud Native Innovations Leave Organizations More Vulnerable to Attacks.
CyberArk named an Overall Leader in the KuppingerCole Analysts 2025 Leadership Compass for Enterprise Secrets Management. (2)
(2) KuppingerCole Analysts '2025 Leadership Compass for Enterprise Secrets Management,' by Martin Kuppinger, April 28, 2025.
Business Outlook
Based on information available as of May 13, 2025, CyberArk is issuing guidance for the second quarter and full year 2025 as indicated below. The guidance for the second quarter and full year 2025 includes the expected contribution from the acquisition of Venafi, which closed on October 1, 2024 and the acquisition of Zilla Security, which closed on February 12, 2025. The comparable periods in 2024 did not include financial contributions from the acquisitions of Venafi and Zilla Security.
Second Quarter 2025:
Total revenue is expected to be in the range of $312.0 million and $318.0 million.
Non-GAAP operating income is expected to be in the range of $41.5 million to $46.5 million.
Non-GAAP net income per share is expected to be in the range of $0.74 to $0.81 per diluted share.
Assumes 51.5 million weighted average diluted shares.
Full Year 2025:
Total revenue is expected to be in the range of $1.313 billion to $1.323 billion, representing growth of 31 percent to 32 percent compared to the full year 2024.
Non-GAAP operating income is expected to be in the range of $221.0 million to $229.0 million.
Non-GAAP net income per share is expected to be in the range of $3.73 to $3.85 per diluted share.
Assumes 51.6 million weighted average diluted shares.
ARR as of December 31, 2025 is expected to be in the range of $1.410 billion to $1.420 billion, representing growth of 21 percent from December 31, 2024.
Adjusted free cash flow is expected to be in the range of $300.0 million to $310.0 million for the full year 2025. Adjusted free cash flow guidance normalizes for a one-time tax payment of $42 million and approximately $15 million in capital expenditures related to our new U.S. headquarters, both of which are discussed below.
Tax Payment Related to Transfer of Venafi IP
CyberArk's forward-looking guidance for adjusted free cash flow for the full year 2025 excludes the estimated impact of an approximately $42 million one-time tax payment related to the capital gain associated with the intercompany migration of intellectual property related to the Venafi acquisition. We expect this to occur in the second quarter of 2025.
This estimated tax payment represents our best estimate of the tax payment related to the IP transfer based on current assumptions and information available. The final tax liability will ultimately be dependent on and could be affected by a number of factors including, but not limited to, deductions based on our stock price, income recognition and/or deductibility of deferred items, eligibility to and utilization of tax credits and other tax deductions, and intercompany payments in the fiscal year 2025.
Capital Expenditures Related to our New U.S. Headquarters
CyberArk's forward-looking guidance for adjusted free cash flow for the full year 2025 excludes the estimated capital expenditures of approximately $15 million related to leasehold improvements to our new U.S. headquarters.
New Presentation of Revenue Line Items
Beginning in the first quarter of 2025, CyberArk is revising the presentation of its lines of revenue and cost of revenue by combining the revenues and cost of revenues previously reported under the 'Perpetual license' line and 'Maintenance and Professional Services' line under the 'Maintenance, Professional Services and Other' line. The Company believes this presentation of revenue and cost of revenue on the consolidated statement of operations aligns with how management evaluates the business. Historical information by quarter for fiscal years 2023 and 2024, which has been retroactively reclassified to reflect the new lines of revenue and cost of revenue, can be found in the PowerPoint presentation posted to CyberArk's investor relations website.
Conference Call Information
In conjunction with this announcement, CyberArk will host a conference call on Tuesday, May 13, 2025 at 8:30 a.m. Eastern Time (ET) to discuss the company's first quarter financial results and its business outlook. To access this call, dial +1 (888) 330-2455 (U.S.) or +1 (240) 789-2717 (international). The conference ID is 6515982. Additionally, a live webcast of the conference call will be available via the 'Investor Relations' section of the company's website at www.cyberark.com.
Following the conference call, a replay will be available for one week at +1 (800) 770-2030 (U.S.) or +1 (609) 800-9909 (international). The replay pass code is 6515982. An archived webcast of the conference call will also be available in the 'Investor Relations' section of the company's website at www.cyberark.com.
About CyberArk
CyberArk (NASDAQ: CYBR) is the global leader in identity security, trusted by organizations around the world to secure human and machine identities in the modern enterprise. CyberArk's AI-powered Identity Security Platform applies intelligent privilege controls to every identity with continuous threat prevention, detection and response across the identity lifecycle. With CyberArk, organizations can reduce operational and security risks by enabling zero trust and least privilege with complete visibility, empowering all users and identities, including workforce, IT, developers and machines, to securely access any resource, located anywhere, from everywhere. Learn more at cyberark.com.
Copyright © 2025 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
Key Performance Indicators and Non-GAAP Financial Measures
Recurring Revenue
Recurring Revenue is defined as revenue derived from SaaS and self-hosted subscription contracts, and maintenance contracts related to perpetual licenses during the reported period.
Annual Recurring Revenue (ARR)
ARR is defined as the annualized value of active SaaS, self-hosted subscriptions and their associated maintenance and support services, and maintenance contracts related to the perpetual licenses in effect at the end of the reported period.
Subscription Portion of Annual Recurring Revenue
Subscription portion of ARR is defined as the annualized value of active SaaS and self-hosted subscription contracts in effect at the end of the reported period. The subscription portion of ARR excludes maintenance contracts related to perpetual licenses.
Maintenance Portion of Annual Recurring Revenue
Maintenance portion of ARR is defined as the annualized value of active maintenance contracts related to perpetual licenses. The Maintenance portion of ARR excludes SaaS and self-hosted subscription contracts in effect at the end of the reported period.
Net New ARR
Net new ARR refers to the difference between ARR as of March 31, 2025 and ARR as of December 31, 2024.
Annual Recurring Revenue (ARR), Subscription portion of ARR and Maintenance portion of ARR are performance indicators that provide more visibility into the growth of our recurring business in the upcoming year. This visibility allows us to make informed decisions about our capital allocation and level of investment. Each of these measures should be viewed independently of revenues and total deferred revenue as each is an operating measure and is not intended to be combined with or to replace either of those measures. ARR, Subscription portion of ARR and Maintenance portion of ARR are not forecasts of future revenues and can be impacted by contract start and end dates and renewal rates.
Non-GAAP Financial Measures
CyberArk believes that the use of non-GAAP gross profit, non-GAAP operating expense, non-GAAP operating income, non-GAAP net income, free cash flow and adjusted free cash flow is helpful to our investors. These financial measures are not measures of the Company's financial performance under U.S. GAAP and should not be considered as alternatives to gross profit, operating loss, net income or net cash provided by operating activities or any other performance measures derived in accordance with GAAP.
Non-GAAP gross profit is calculated as GAAP gross profit excluding share-based compensation expense, and amortization of intangible assets related to acquisitions.
Non-GAAP operating expense is calculated as GAAP operating expenses excluding share-based compensation expense, acquisition related expenses, and amortization of intangible assets related to acquisitions.
Non-GAAP operating income is calculated as GAAP operating loss excluding share-based compensation expense, acquisition related expenses, and amortization of intangible assets related to acquisitions.
Non-GAAP net income is calculated as GAAP net income excluding share-based compensation expense, acquisition related expenses, amortization of intangible assets related to acquisitions, amortization of debt discount and issuance costs and tax adjustments.
Free cash flow is calculated as net cash provided by operating activities less purchase of property and equipment and other assets, and capitalized internal-use software.
Adjusted free cash flow is calculated as free cash flow plus one-time tax payment on the capital gain from the intercompany migration of intellectual property (IP) related to the Venafi acquisition and capital expenditures related to our new U.S. headquarters.
The Company believes that providing non-GAAP financial measures that are adjusted by, as applicable, share-based compensation expense, acquisition related expenses, amortization of intangible assets related to acquisitions, amortization of debt discount and issuance cost, tax adjustments, purchase of property and equipment and other assets, capitalized internal-use software, one-time tax payment on the capital gain from the intercompany migration of intellectual property, and capital expenditures related to our new U.S. headquarters allows for more meaningful comparisons of its period to period operating results. Share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company's business and an important part of the compensation provided to its employees. Share-based compensation expense has varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expense. The Company believes that expenses related to its acquisitions, amortization of intangible assets related to acquisitions, and amortization of debt discount and issuance costs do not reflect the performance of its core business and impact period-to-period comparability. The Company believes free cash flow and adjusted free cash flow are liquidity measures that, after the purchase of property and equipment and other assets, capitalized internal-use software, one-time tax payment on the capital gain from the intercompany migration of intellectual property, and capital expenditures related to our new U.S. headquarters provide useful information about the amount of cash generated by the business.
Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures as they exclude expenses that may have a material impact on the Company's reported financial results. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with U.S. GAAP. CyberArk urges investors to review the reconciliation of its non-GAAP financial measures to the comparable U.S. GAAP financial measures included below, and not to rely on any single financial measure to evaluate its business.
Beginning in the first quarter of 2025, we will utilize a fixed projected non-GAAP tax rate when calculating non-GAAP financial measures to provide better consistency across interim reporting periods. In projecting this rate, we exclude the effects of certain non-recurring items, which do not necessarily reflect our normal operations, and the direct income tax effects of other non-GAAP adjustments. The fixed projected non-GAAP tax rate is based on annual financial projections and reflects our evaluation of historical and projected geographic earnings mix within our operating structure, recurring tax credits, existing tax positions in various jurisdictions and current impacts from key legislation. Based on these considerations, we applied a fixed projected non-GAAP tax rate for 2025 of 24%. We will provide updates to this rate on an annual basis, or more frequently, if significant events have a material impact on the rate. The rate could be subject to change for a variety of reasons, such as significant changes in the geographic earnings mix, relevant tax law changes in major jurisdictions where we operate, or significant acquisitions.
Guidance for non-GAAP financial measures excludes, as applicable, share-based compensation expense, acquisition related expenses, amortization of intangible assets related to acquisitions, tax adjustments, purchase of property and equipment and other assets, one-time tax payment on the capital gain from the intercompany migration of intellectual property, and capital expenditures related to our new U.S. headquarters. A reconciliation of the non-GAAP financial measures guidance to the corresponding GAAP measures is not available on a forward-looking basis due to the uncertainty regarding, and the potential variability and significance of, the amounts of share-based compensation expense, amortization of intangible assets related to acquisitions, and the non-recurring expenses that are excluded from the guidance, as well as changes in interest rates and foreign exchange rates, which impact other GAAP performance metrics or liquidity measures. Accordingly, a reconciliation of the non-GAAP financial measures guidance to the corresponding GAAP measures for future periods is not available without unreasonable effort.
Cautionary Language Concerning Forward-Looking Statements
This release contains forward-looking statements, which express the current beliefs and expectations of CyberArk's (the 'Company') management. In some cases, forward-looking statements may be identified by terminology such as 'believe,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'expect,' 'predict,' 'potential' or the negative of these terms or other similar expressions. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to: risks related to the Company's acquisitions of Venafi Holdings, Inc. ('Venafi') and Zilla Security Inc. ('Zilla'), including potential impacts on operating results; challenges in retaining and hiring key personnel and maintaining Venafi and Zilla business; risks related to the successful integration of the operations of Venafi or Zilla and the ability to realize anticipated benefits of the combined operations; the rapidly evolving security market, increasingly changing cyber threat landscape and the Company's ability to adapt its solutions to the information security market changes and demands; the Company's ability to acquire new customers and maintain and expand its revenues from existing customers; real or perceived security vulnerabilities and gaps in the Company's solutions or services or the failure of customers or third parties to correctly implement, manage and maintain solutions; the Company's IT network systems, or those of third-party providers, may be compromised by cyberattacks or other security incidents, or by a critical system disruption or failure; intense competition within the information security market; failure to fully execute, integrate, or realize the benefits expected from strategic alliances, partnerships, and acquisitions; the Company's ability to effectively execute its sales and marketing strategies, and expand, train and retain its sales personnel; risks related to the Company's compliance with privacy, data protection and AI laws and regulations; the Company's ability to hire, upskill, retain and motivate qualified personnel; risks related to the integration of AI technology into our operations and solutions; reliance on third-party cloud providers for the Company's operations and software-as-a-service (SaaS) solutions; the Company's ability to maintain successful relationships with channel partners, or if channel partners fail to perform; fluctuation in the Company's quarterly results of operations; risks related to sales made to government entities; economic uncertainties or downturns; the Company's history of incurring net losses, its ability to generate sufficient revenue to achieve and sustain profitability and its ability to generate cash flow from operating activities; regulatory and geopolitical risks associated with the Company's global sales and operations; risks related to intellectual property; fluctuations in currency exchange rates; the ability of the Company's solutions to help customers achieve and maintain compliance with government regulations or industry standards; the Company's ability to protect its proprietary technology and intellectual property rights; risks related to using third-party software, such as open-source software and other intellectual property; risks related to share price volatility or activist shareholders; any failure to retain the Company's 'foreign private issuer' status or the risk that the Company may be classified, for U.S. federal income tax purposes, as a 'passive foreign investment company'; risks related to issuance of ordinary shares or securities convertible into ordinary shares and dilution, leading to a decline in the market value of the Company's ordinary shares; changes in tax laws; the Company's expectation to not pay dividends on its ordinary shares for the foreseeable future; risks related to the Company's incorporation and location in Israel, including wars and other hostilities in the Middle East; and other factors discussed under the heading 'Risk Factors' in the Company's most recent annual report on Form 20-F filed with the Securities and Exchange Commission. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company disclaims any obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
CYBERARK SOFTWARE LTD.
Consolidated Balance Sheets
U.S. dollars in thousands
(Unaudited)
December 31, March 31,
2024
2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
526,467
$
413,554
Short-term bank deposits
256,953
235,396
Marketable securities
36,356
73,440
Trade receivables
328,465
229,972
Prepaid expenses and other current assets
45,292
56,862
Total current assets
1,193,533
1,009,224
LONG-TERM ASSETS:
Marketable securities
21,345
53,725
Property and equipment, net
19,581
21,334
Intangible assets, net
534,726
555,915
Goodwill
1,317,374
1,444,680
Other long-term assets
258,531
246,087
Deferred tax asset
3,305
7,003
Total long-term assets
2,154,862
2,328,744
TOTAL ASSETS
$
3,348,395
$
3,337,968
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables
$
23,671
$
19,492
Employees and payroll accruals
133,400
84,337
Accrued expenses and other current liabilities
53,486
80,124
Deferred revenues
596,874
600,309
Total current liabilities
807,431
784,262
LONG-TERM LIABILITIES:
Deferred revenues
95,190
90,709
Other long-term liabilities
75,970
35,290
Total long-term liabilities
171,160
125,999
TOTAL LIABILITIES
978,591
910,261
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.01 par value
130
131
Additional paid-in capital
2,494,158
2,543,671
Accumulated other comprehensive income (loss)
2,173
(901
)
Accumulated deficit
(126,657
)
(115,194
)
Total shareholders' equity
2,369,804
2,427,707
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$
3,348,395
$
3,337,968
Expand
CYBERARK SOFTWARE LTD.
Consolidated Statements of Cash Flows
U.S. dollars in thousands
(Unaudited)
Three Months Ended
March 31,
2024
2025
Cash flows from operating activities:
Net income
$
5,470
$
11,463
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization
4,021
31,624
Amortization of premium and accretion of discount on marketable securities, net
(1,866
)
(26
)
Share-based compensation
37,499
48,202
Deferred income taxes, net
(1,052
)
(45,549
)
Decrease in trade receivables
47,156
100,338
Amortization of debt discount and issuance costs
751
-
Increase in prepaid expenses, other current and long-term assets and others
(5,803
)
(6,917
)
Changes in operating lease right-of-use assets
1,909
2,748
Decrease in trade payables
(7,323
)
(4,816
)
Increase (decrease) in short-term and long-term deferred revenues
20,656
(5,943
)
Decrease in employees and payroll accruals
(28,012
)
(49,060
)
Increase (decrease) in accrued expenses and other current and long-term liabilities
(2,383
)
19,327
Changes in operating lease liabilities
(2,388
)
(2,863
)
Net cash provided by operating activities
68,635
98,528
Cash flows from investing activities:
Investment in short and long term deposits
(156,382
)
(63,806
)
Proceeds from short and long term deposits
164,800
86,252
Investment in marketable securities
(92,343
)
(76,118
)
Proceeds from maturities of marketable securities
102,686
7,104
Purchase of property and equipment and other assets
(1,356
)
(1,699
)
Capitalized internal-use software
(509
)
(1,307
)
Payments for business acquisitions, net of cash acquired
-
(164,383
)
Net cash provided by (used in) investing activities
16,896
(213,957
)
Cash flows from financing activities:
Payment of withholding tax related to employee stock plans
(6,327
)
(6,397
)
Proceeds from exercise of stock options
3,358
907
Proceeds in connection with employees stock purchase plan
4,848
6,119
Net cash provided by financing activities
1,879
629
Increase (decrease) in cash and cash equivalents
87,410
(114,800
)
Effect of exchange rate differences on cash and cash equivalents
(2,819
)
1,887
Cash and cash equivalents at the beginning of the period
355,933
526,467
Cash and cash equivalents at the end of the period
$
440,524
$
413,554
Expand
CYBERARK SOFTWARE LTD.
Reconciliation of GAAP Measures to Non-GAAP Measures
U.S. dollars in thousands (except per share data)
(Unaudited)
Reconciliation of Net cash provided by operating activities to Free cash flow:
Three Months Ended
March 31,
2024
2025
Net cash provided by operating activities
$
68,635
$
98,528
Less:
Purchase of property and equipment and other assets
(1,356
)
(1,699
)
Capitalized internal-use software
(509
)
(1,307
)
Free cash flow
$
66,770
$
95,522
GAAP net cash provided by (used in) investing activities
16,896
(213,957
)
GAAP net cash provided by financing activities
1,879
629
Reconciliation of Gross Profit to Non-GAAP Gross Profit:
Three Months Ended
March 31,
2024
2025
Gross profit
$
179,142
$
241,340
Plus:
Share-based compensation (1)
4,820
5,692
Amortization of share-based compensation capitalized in software development costs (3)
72
94
Amortization of intangible assets (2)
1,704
21,447
Non-GAAP gross profit
$
185,738
$
268,573
Reconciliation of Operating Expenses to Non-GAAP Operating Expenses:
Three Months Ended
March 31,
2024
2025
Operating expenses
$
185,520
$
262,073
Less:
Share-based compensation (1)
32,679
42,510
Amortization of intangible assets (2)
125
7,425
Acquisition related expenses
-
1,105
Non-GAAP operating expenses
$
152,716
$
211,033
Reconciliation of Operating loss to Non-GAAP Operating Income:
Three Months Ended
March 31,
2024
2025
Operating loss
$
(6,378
)
$
(20,733
)
Plus:
Share-based compensation (1)
37,499
48,202
Amortization of share-based compensation capitalized in software development costs (3)
72
94
Amortization of intangible assets (2)
1,829
28,872
Acquisition related expenses
-
1,105
Non-GAAP operating income
$
33,022
$
57,540
Reconciliation of Net Income to Non-GAAP Net Income:
Three Months Ended
March 31,
2024
2025
Net income
$
5,470
$
11,463
Plus:
Share-based compensation (1)
37,499
48,202
Amortization of share-based compensation capitalized in software development costs (3)
72
94
Amortization of intangible assets (2)
1,829
28,872
Acquisition related expenses
-
1,105
Amortization of debt discount and issuance costs
751
-
Tax adjustments (4)
(9,752
)
(39,439
)
Non-GAAP net income
$
35,869
$
50,297
Non-GAAP net income per share
Basic
$
0.85
$
1.01
Diluted
$
0.75
$
0.98
Weighted average number of shares
Basic
42,430,559
49,589,733
(1) Share-based Compensation :
Three Months Ended
March 31,
2024
2025
Cost of revenues - Subscription
$
1,412
$
2,006
Cost of revenues - Maintenance, Professional Services and Other
3,408
3,686
Research and development
7,560
11,026
Sales and marketing
14,879
18,593
General and administrative
10,240
12,891
Total share-based compensation
$
37,499
$
48,202
(2) Amortization of intangible assets :
Three Months Ended
March 31,
2024
2025
Cost of revenues - Subscription
$
1,704
$
21,447
Sales and marketing
125
7,425
Total amortization of intangible assets
$
1,829
$
28,872
(3) Classified as Cost of revenues - Subscription.
(4) Beginning in the first quarter of 2025, we will utilize a fixed projected non-GAAP tax rate in calculating non-GAAP financial measures to provide better consistency across interim reporting periods. In projecting this rate, we exclude the effects of certain non-recurring items, which do not necessarily reflect our normal operations, and the direct income tax effects of other non-GAAP adjustments. The fixed projected non-GAAP tax rate is based on annual financial projections and reflects our evaluation of historic and projected geographic earnings mix within our operating structure, recurring tax credits, existing tax positions in various jurisdictions and current impacts from key legislation. Based on these considerations, we applied a fixed projected non-GAAP tax rate for 2025 of 24%. The tax adjustments for the first quarter of 2024 include income tax adjustments related to non-GAAP items.
Expand

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence
Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence

Business Upturn

time26 minutes ago

  • Business Upturn

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence

SAN FRANCISCO, June 15, 2025 (GLOBE NEWSWIRE) — Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and operational challenges. Most recently, on May 5, 2025, Napco released its third-quarter financial results for fiscal year 2025, revealing mixed performance metrics amid an ongoing securities class action lawsuit that centers on its distribution practices and sales forecasting. Hagens Berman is investigating the alleged claims and urges Napco investors who suffered substantial losses to submit your losses now. Class Period: Feb. 5, 2024 – Feb. 3, 2025 Lead Plaintiff Deadline: June 24, 2025 Visit: Contact the Firm Now: [email protected] 844-916-0895 Third Quarter Financial Overview Napco's third-quarter results showed a 10.8% year-over-year drop in net sales, totaling $43.96 million. While the company managed to surpass earnings-per-share expectations—reporting $0.36 per share versus a $0.29 forecast—overall revenue missed Wall Street estimates, and net income declined by over 23% compared to the previous year. The company attributed the sales shortfall primarily to inventory reductions by key distributors, a factor that has become central to the ongoing lawsuit. Background of the Securities Class Action The class action, filed as Patel v. Napco Security Technologies, Inc., et al ., alleges that Napco's leadership misled investors about its ability to accurately predict hardware demand and sustain ambitious margin targets for fiscal 2026. The complaint claims that despite public assurances of strong hardware division growth and effective forecasting, Napco failed to disclose vulnerabilities in its distribution network and the risks associated with relying on a limited number of major distributors. The situation escalated after the company's February 3, 2025, earnings report, which revealed a 25% decrease in equipment sales and prompted Napco to withdraw its 45% EBITDA margin target for fiscal 2026. These disclosures led to a dramatic 26% decline in Napco's share price in a single trading session, erasing nearly $10 per share in value. Allegations and Share Price Impact Plaintiffs allege that Napco's optimistic statements about its sales pipeline and margin outlook were misleading, given the company's inability to accurately forecast demand and the impact of distributor inventory adjustments. The lawsuit contends that these omissions artificially inflated Napco's stock price during the class period, causing substantial losses when the true financial picture emerged. Specifically, on February 3rd, Napco released disappointing second-quarter fiscal 2025 results, revealing a substantial 25% drop in equipment sales compared to the prior year's second quarter, along with significant declines in gross margin and gross profit for equipment revenue. The company attributed this disappointing performance to 'reduced sales to two of our larger distributors,' with one distributor explicitly citing efforts to reduce its inventory levels. These disclosures caused Napco's shares to plummet 26% over a single trading day. Hagens Berman's Investigation Prominent shareholder rights firm Hagens Berman is actively investigating the allegations against Napco, focusing on whether the company misled investors regarding its sales forecasting and distribution practices. 'Investors deserve transparency, especially when a company's future growth is tied so closely to its ability to manage demand and distribution. When those fundamentals are called into question, as we believe they are here, it's our job to ensure shareholders get clear answers and accountability,' said Reed Kathrein, the Hagens Berman partner overseeing the investigation. If you invested in Napco and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Napco case and our investigation, read more » Whistleblowers: Persons with non-public information regarding Napco should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Business Upturn

time26 minutes ago

  • Business Upturn

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Business Upturn

time26 minutes ago

  • Business Upturn

EGBN Investor News: If You Have Suffered Losses in Eagle Bancorp, Inc. (NASDAQ: EGBN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. (NASDAQ: EGBN) resulting from allegations that Eagle Bancorp may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Eagle Bancorp securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On April 23, 2025, after market hours, Eagle Bancorp filed with the SEC a current report on Form 8-K, which included an announcement of Eagle Bancorp's Q1 2025 results. Commenting on these results, an article posted on the next day stated that Eagle Bancorp's Q1 2025 announcement revealed a ' notable miss on both earnings per share (EPS) and revenue compared to forecasts.' On this news, Eagle Bancorp's stock price fell 11.3% on April 24, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store